Two types of biochar help alfalfa survive salty soils in different ways
Peer-Reviewed Publication
Updates every hour. Last Updated: 17-Jun-2026 02:16 ET (17-Jun-2026 06:16 GMT/UTC)
Scientists have developed a new way to improve the reliability of DNA origami for future biomedical, agritech and other technological applications.
Albert Einstein College of Medicine has launched the Batia and Idan Ofer program for Validation of Interventions Targeting Aging and Longevity (BIO-VITAL), a new initiative designed to help biotechnology and pharmaceutical companies advance therapies that target the biology of aging.
Rhodoliths may look like small rocks on the seafloor, but they're actually living algae that create habitats for marine life and contribute to long-term carbon storage. A new study found that the deeper ‘low-light’ waters off Japan's Tanegashima Island harbor a surprisingly distinct and diverse community of these ‘living pink rocks,’ including four species completely new to science. Researchers identified at least 12 species in a small patch of seafloor 35–38 meters deep, but only three were also found in nearby shallow waters, suggesting the deeper habitat is not simply a continuation of the one near the surface.
Nanjing University researchers report a breakthrough siRNA delivery strategy that transforms the liver into a "biopharmaceutical factory" for targeted cancer therapy. The team developed an In Vivo Self-Assembled (IVSA) system that uses intravenously injected plasmid DNA to program hepatocytes to produce and package EGFR-targeting siRNA into GE11-tagged small extracellular vesicles. These "biomissiles" selectively deliver therapeutic siRNA to EGFR-positive tumors, overcoming the long-standing siRNA delivery challenge without complex in vitro encapsulation. The system demonstrated potent efficacy across EGFR-mutant lung cancer, gastric cancer, and breast cancer models, outperforming traditional targeted drugs while showing minimal off-target toxicity. This plug-and-play platform represents a paradigm shift from conventional drug manufacturing to in vivo biopharmaceutical production, offering a modular, cost-effective approach for personalized cancer gene therapy.